H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Caladrius Biosciences (CLBS – Research Report) today and set a price target of $18.50. The company’s shares closed yesterday at $4.10, close to its 52-week low of $3.05.
“Valuation and risks to price target achievement; only need a little to be potentially quite meaningful. We reiterate our Buy rating and $18.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. As part of our valuation projections, we make the following assumptions, which we also believe provide additional levels of conservatism to our projections.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -16.0% and a 28.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.
Based on Caladrius Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.55 million. In comparison, last year the company had a GAAP net loss of $2.75 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.